Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241776 | 0.83 | MAP4K4 (0.57) | MAP3K12ALOX5APMAP4K4 | |
| SCHEMBL20898739 | 0.81 | MAP3K12 (0.40) | MAP3K12MAP4K4FGFR1FGFR4FGFR3 | |
| SCHEMBL881807 | 0.78 | ALOX5AP (0.45) | ALOX5APMAP4K4 | |
| SCHEMBL10241314 | 0.76 | MAP4K4 (0.53) | MAP3K12ALOX5APMAP4K4 | |
| SCHEMBL15167079 | 0.76 | MAP4K4 (0.39) | MAP3K12MAP4K4FGFR1FGFR4FGFR3 | |
| SCHEMBL23601698 | 0.76 | CHRNB4 (0.38) | MAP3K12ALOX5APMAP4K4FGFR1FGFR4 | |
| SCHEMBL877334 | 0.74 | MAP3K12 (0.35) | MAP3K12MAP4K4FGFR1FGFR4FGFR3 | |
| SCHEMBL12940523 | 0.74 | OPRM1 (0.37) | MAP3K12MAP4K4FGFR1FGFR4FGFR3 | |
| SCHEMBL23008877 | 0.74 | FFAR4 (0.39) | MAP3K12MAP4K4FGFR1FGFR4FGFR3 | |
| SCHEMBL18033990 | 0.74 | OPRM1 (0.38) | MAP3K12FGFR1FGFR4FGFR3FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619197-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2619197-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8575201-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575201-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575201-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| EP-2619197-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012040139-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | MAP3K12 3168/4885ALOX5AP 16/4885MAP4K4 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.